Norethindrone Drug-Drug Interactions: The Complete Profile for Women

What Norethindrone Is and How It Works

Norethindrone is a synthetic progestogen derived from the 19-nortestosterone backbone. It acts primarily at progesterone receptors in the endometrium, hypothalamus, and cervix. The drug suppresses the LH surge, thickens cervical mucus, and renders the endometrium atrophic, each mechanism contributing to its three distinct clinical uses: contraception, heavy menstrual bleeding reduction, and endometriosis suppression.

Because it is derived from testosterone, norethindrone also carries measurable androgenic activity, which separates it pharmacodynamically from progesterone or medroxyprogesterone acetate. That androgenic signature matters for interactions: drugs that alter androgen receptor sensitivity or sex hormone binding globulin (SHBG) can shift the free-to-bound ratio of norethindrone in circulation.

Two Different Dose Forms, Two Different Clinical Contexts

Norethindrone 0.35 mg tablets (the progestin-only pill, or POP, sold as Camila, Errin, Jolivette, and generics) are used for contraception, particularly in women who cannot use estrogen. Norethindrone acetate 5 mg tablets (Aygestin and generics) are used for endometriosis and HMB. The FDA prescribing information for norethindrone acetate classifies the 5 mg tablet as Pregnancy Category X.

The Mechanism That Creates Most Interactions

Norethindrone is extensively metabolized in the liver, primarily by CYP3A4, with secondary contributions from CYP1A2, sulfotransferases, and UDP-glucuronosyltransferases. Any drug that induces or inhibits CYP3A4 will alter norethindrone exposure in a clinically meaningful way. The progestin-only pill has almost no pharmacokinetic buffer: its contraceptive effect depends on maintaining trough concentrations above a narrow threshold, so even a modest induction can push levels below that threshold.

Strong CYP3A4 Inducers: The Highest-Risk Category

Strong CYP3A4 inducers are the most dangerous class of interacting drugs for women using norethindrone as contraception. These agents accelerate hepatic metabolism and can reduce norethindrone area under the curve (AUC) by 40 to 57 percent, a drop large enough to cause ovulation in some women.

Rifamycin Antibiotics

Rifampin (rifampicin) is the most studied and most potent inducer in this class. A pharmacokinetic study published in the context of combined hormonal contraceptive data showed that rifampin reduced ethinyl estradiol and progestin plasma levels by more than 50 percent, and the interaction is expected to be at least as severe with the progestin-only pill because there is no estrogen component to partially compensate. ACOG Practice Bulletin 206 advises that women requiring rifampin-based tuberculosis therapy use a non-hormonal or long-acting reversible contraceptive method instead. Rifabutin, used in HIV-TB coinfection, is a weaker inducer but still clinically significant.

Antiepileptic Drugs

Women with epilepsy are disproportionately affected here, because they often require long-term anticonvulsant therapy during their reproductive years and perimenopause. The enzyme-inducing antiepileptic drugs (EIAEDs) most relevant to norethindrone include:

• Phenytoin
• Carbamazepine
• Phenobarbital
• Primidone
• Oxcarbazepine (moderate inducer)
• Topiramate at doses above 200 mg/day

A 2022 review in Epilepsia confirmed that EIAEDs reduce progestin concentrations to sub-therapeutic levels and that the progestin-only pill should not be considered reliable contraception in women on these agents. Non-enzyme-inducing alternatives such as lamotrigine, levetiracetam, and valproate do not carry this interaction risk. For women with epilepsy using norethindrone acetate 5 mg for endometriosis rather than contraception, the clinical concern shifts from contraceptive failure to subtherapeutic endometriosis control.

Antiretrovirals

Several HIV antiretroviral agents are strong or moderate CYP3A4 inducers. Ritonavir is the most complex: at low "boosting" doses it behaves as both an inducer and inhibitor depending on the substrate, and its net effect on norethindrone is a modest reduction in exposure. The FDA Drug Interactions for Hormonal Contraceptives guidance recommends backup or alternative contraception for women on ritonavir-boosted regimens. Efavirenz, a non-nucleoside reverse transcriptase inhibitor common in low-resource settings, is a well-characterized CYP3A4 inducer that reduces progestin levels.

Herbal Inducers: St. John's Wort

St. John's wort (Hypericum perforatum) is not a prescription drug, but its use is common and frequently undisclosed. It induces CYP3A4 and P-glycoprotein through activation of the pregnane X receptor. Published case series document breakthrough bleeding and contraceptive failures in women combining St. John's wort with oral progestins. Ask every patient directly whether she uses herbal supplements.

CYP3A4 Inhibitors: When Norethindrone Levels Rise

The opposite problem is equally important but less often discussed. Strong CYP3A4 inhibitors reduce the breakdown of norethindrone, raising plasma concentrations and potentially amplifying both therapeutic and adverse effects (irregular bleeding, androgenic side effects, mood changes).

Azole Antifungals

Fluconazole is the most commonly prescribed strong CYP3A4 inhibitor in women, given its widespread use for vulvovaginal candidiasis. A single 150 mg dose of fluconazole raises the AUC of CYP3A4-metabolized progestins. For a woman using the 0.35 mg progestin-only pill, a transient spike in norethindrone exposure is unlikely to be dangerous. For a woman on 5 mg norethindrone acetate for endometriosis who is also using fluconazole for recurrent Candida, the accumulation across multiple doses warrants clinical monitoring for androgenic effects and irregular bleeding. Itraconazole and ketoconazole carry similar inhibitory potency.

Macrolide Antibiotics

Clarithromycin and erythromycin are moderate-to-strong CYP3A4 inhibitors. Azithromycin, by contrast, does not inhibit CYP3A4 at standard doses and is a safe antibiotic choice for women on norethindrone when macrolide therapy is indicated. This distinction is clinically actionable.

Grapefruit Juice

Grapefruit and Seville orange juice contain furanocoumarins that irreversibly inhibit intestinal CYP3A4. The interaction with low-dose progestin-only pills is not well-quantified in women specifically, but the mechanism is established. Women taking norethindrone acetate 5 mg, where consistent dosing matters for endometriosis suppression, should be counseled to avoid large daily quantities of grapefruit juice.

Pharmacodynamic Interactions: Beyond Enzyme Induction

Not all norethindrone interactions run through CYP3A4. Several important interactions are pharmacodynamic, meaning they involve competing or additive effects at hormone-sensitive tissues rather than altered drug levels.

Interactions With Estrogen-Containing Therapies

When norethindrone is combined with estrogen (as in menopausal hormone therapy or combined oral contraceptives), the estrogen component raises SHBG, which binds norethindrone and reduces its free fraction. This is not inherently harmful; combined pills exploit this balance intentionally. The clinical problem arises when a woman on menopausal hormone therapy containing estradiol and norethindrone acetate also takes a drug that suppresses SHBG (such as an androgen or an androgenic anabolic steroid), freeing more norethindrone and increasing androgenic side effects.

Interactions With Drugs That Alter Glucose Metabolism

Norethindrone has modest insulin-antagonizing properties due to its androgenic activity. This effect is dose-dependent and most relevant at the 5 mg norethindrone acetate dose. Women with PCOS already have insulin resistance, and those who also take corticosteroids, atypical antipsychotics (especially olanzapine and clozapine), or high-dose thiazide diuretics face additive insulin resistance when norethindrone is added. A systematic review examining progestogen effects on insulin sensitivity found that 19-nortestosterone derivatives, including norethindrone, produced greater glucose dysregulation than progesterone or dydrogesterone in women with pre-existing metabolic risk.

Interactions With Lamotrigine (Reversed Direction)

This interaction deserves its own discussion because the direction of harm runs opposite to most anticonvulsant interactions. Lamotrigine clearance is increased by estrogen-containing contraceptives, but norethindrone-only preparations do not meaningfully alter lamotrigine pharmacokinetics. For a woman with epilepsy who switches from a combined pill to the progestin-only norethindrone pill, lamotrigine levels may rise as the estrogen-mediated induction is removed, potentially causing lamotrigine toxicity (dizziness, diplopia, ataxia). The 2022 Epilepsy Foundation guidance recommends lamotrigine serum level monitoring at the time of this switch.

Interactions With Anticoagulants

Norethindrone has been documented to increase the metabolism of certain vitamin K antagonists. Case reports describe reduced warfarin efficacy in women starting norethindrone acetate, requiring upward INR monitoring and dose adjustment. Women on warfarin for mechanical heart valves or antiphospholipid antibody syndrome, both conditions more heavily managed in reproductive-age women, need INR checks within two to four weeks of starting or stopping norethindrone acetate.

Norethindrone and the Menstrual Cycle: Why Timing Matters for Interactions

The interaction risk is not static across the cycle. Norethindrone plasma concentrations vary slightly depending on whether a woman is taking the POP continuously or cycling the 5 mg acetate form. During the follicular phase, baseline CYP3A4 activity is modestly higher than in the luteal phase in cycling women, according to sex-specific pharmacokinetic data. This means a CYP3A4 inducer started in the early follicular phase may lower norethindrone levels at a time when the contraceptive margin is already narrower. Women switching between formulations or adding an interacting drug mid-cycle should use barrier backup for at least seven days.

Pregnancy, Lactation, and Contraception Requirements

Pregnancy: Contraindicated.

Norethindrone acetate 5 mg (Aygestin) carries FDA Pregnancy Category X designation. Exposure to synthetic progestins during organogenesis has been associated with genital virilization in female fetuses in older case series, though the absolute risk with short inadvertent exposure is considered low by current data. Any woman of reproductive age prescribed norethindrone acetate 5 mg for endometriosis or HMB must use reliable non-hormonal or intrauterine contraception concurrently, because the drug does not itself reliably suppress ovulation at that dose.

The 0.35 mg progestin-only contraceptive pill is not teratogenic at the dose studied in humans, but it is not indicated for use in confirmed pregnancy. If a woman taking the POP becomes pregnant (failure rate approximately 0.3 to 9 percent with typical use), the drug should be stopped and pregnancy management initiated.

Lactation: Generally Compatible, With Caveats.

Norethindrone is detectable in breast milk. A pharmacokinetic study in lactating women found that the infant receives an estimated 0.1 to 0.3 percent of the maternal weight-adjusted dose, a level considered too low to cause harm based on current data. The progestin-only pill is the preferred hormonal contraceptive in postpartum breastfeeding women after six weeks. ACOG Practice Bulletin 206 supports starting progestin-only contraception at six weeks postpartum in nursing women without contraindications.

Norethindrone acetate 5 mg is not recommended during lactation given the substantially higher dose and limited infant safety data at that exposure level.

Contraception Requirement for the 5 mg Formulation:

Women using norethindrone acetate 5 mg must be counseled explicitly that this formulation does not reliably prevent pregnancy and that a separate, highly effective contraceptive method is required. This is especially relevant in perimenopause, where women often underestimate their residual fertility.

Life-Stage Differences in Interaction Risk

Reproductive Years and Contraceptive Use

Women aged 15 to 44 using norethindrone 0.35 mg as their sole contraceptive method carry the greatest risk from CYP3A4 inducers, because contraceptive failure has direct consequences. The progestin-only pill has a tighter pharmacokinetic margin than combined pills, and the three-hour dosing window for the traditional POP amplifies any drug-level reduction.

PCOS Across Reproductive Years and Into Perimenopause

Women with PCOS are among the most frequent users of progestin-containing medications, both for cycle regulation and endometrial protection. They are also more likely to be on metformin, which does not alter CYP3A4 but does improve insulin sensitivity. Adding norethindrone (particularly the 5 mg dose) to a PCOS regimen already including metformin, inositol supplements, or spironolactone requires attention to overlapping metabolic and hormonal effects. Spironolactone competes at androgen receptors and may partially counteract norethindrone's androgenic activity, an interaction that is pharmacodynamic rather than metabolic.

Perimenopause and Menopause Hormone Therapy

Perimenopausal women are prescribed norethindrone acetate as the progestogen component of sequential or continuous combined HRT, often alongside oral estradiol or conjugated equine estrogens. At this stage, they are also more likely to be on statins, antihypertensives, and antidepressants. SSRIs and SNRIs do not inhibit CYP3A4 significantly (fluoxetine and fluvoxamine are partial exceptions via CYP2D6 and CYP1A2 respectively), but SSRIs in women with perimenopause can independently reduce hot flashes, creating a functional interaction with HRT efficacy that clinicians should track. For women on atorvastatin (a CYP3A4 substrate but not a significant inhibitor), the interaction with norethindrone is bidirectional: norethindrone may modestly increase atorvastatin exposure, a consideration when titrating statin dose.

Postpartum and Lactation

Covered in the section above. The six-week wait before starting any hormonal method is based on venous thromboembolism risk data, not on norethindrone interaction data specifically. The interaction profile in postpartum women is otherwise the same as in reproductive-age non-postpartum women.

Who This Is Right For, and Who Should Reconsider

The following framework synthesizes interaction risk by clinical profile to help clinicians and women have a more precise conversation.

Lower interaction risk, norethindrone generally suitable:

• Women using azithromycin for respiratory infection (no CYP3A4 inhibition)
• Women on SSRIs (sertraline, escitalopram) without fluoxetine
• Women on non-enzyme-inducing antiepileptics (lamotrigine, levetiracetam, valproate), though lamotrigine level monitoring is needed at formulation switch
• Women on metformin for PCOS or diabetes
• Postpartum women after six weeks, breastfeeding without contraindications

Higher interaction risk, close monitoring or alternative method needed:

• Women on rifampin or rifabutin for tuberculosis or MAC prophylaxis: switch to copper IUD or implant
• Women on phenytoin, carbamazepine, phenobarbital, or oxcarbazepine: use long-acting reversible contraception instead of norethindrone 0.35 mg; assess endometriosis control separately if on 5 mg
• Women on efavirenz-based HIV regimens: discuss alternative contraception with their HIV provider
• Women on warfarin: check INR at two and four weeks after starting norethindrone acetate
• Women with PCOS and metabolic syndrome taking corticosteroids: monitor fasting glucose
• Women taking St. John's wort for depression: substitute evidence-based antidepressant and use backup contraception for at least 28 days after stopping the herbal

Contraindicated regardless of interaction profile:

• Confirmed pregnancy (norethindrone acetate 5 mg, Category X)
• Active or past history of hormone-sensitive breast cancer (all norethindrone formulations; discuss with oncologist)
• Active severe hepatic disease (impairs norethindrone metabolism, increasing exposure unpredictably)
• Undiagnosed abnormal uterine bleeding (workup required before initiating)

Monitoring Parameters When Interactions Cannot Be Avoided

When a woman must take norethindrone alongside an interacting drug and switching is not possible, the following monitoring plan is appropriate:

• Contraceptive efficacy: Confirm no missed periods; if breakthrough bleeding occurs on CYP3A4 inducer, treat as potential contraceptive failure and check pregnancy test
• Warfarin co-therapy: INR at two weeks, four weeks, then monthly for three months after starting or stopping norethindrone acetate; target INR range as per underlying indication
• Glucose monitoring in PCOS or pre-diabetes: Fasting glucose and HbA1c at three months after initiating norethindrone acetate 5 mg
• Lamotrigine co-therapy: Serum lamotrigine level within two weeks of switching from combined hormonal to progestin-only norethindrone
• Bone mineral density: Dual-energy X-ray absorptiometry (DEXA) at baseline and after 12 to 24 months for women on norethindrone acetate 5 mg for endometriosis, in line with ACOG guidance on progestogen and bone health
• Androgenic side effects: Assess for acne, seborrhea, and hirsutism at three-month intervals in women on norethindrone acetate 5 mg who are also on fluconazole, clarithromycin, or other CYP3A4 inhibitors

The Evidence Gap in Women-Specific Pharmacokinetics

Women are still under-represented in drug interaction trials. Most of the CYP3A4 interaction data cited in the norethindrone prescribing information was derived from studies using combined oral contraceptives, not the progestin-only formulation, and predominantly in non-pregnant women aged 18 to 40. The extrapolation to perimenopausal women, women with significant insulin resistance, or women with hepatic steatosis (increasingly common in women with PCOS and obesity) rests on mechanistic inference rather than direct trial data.

A 2014 review examining sex differences in CYP3A4 metabolism found that women have approximately 20 to 30 percent higher baseline CYP3A4 activity than men, meaning female-specific interaction magnitudes may differ from those reported in mixed-sex pharmacokinetic studies. This gap should prompt clinicians to apply a wider safety margin when co-prescribing norethindrone with known CYP3A4 modulators in women at metabolic or reproductive risk.

The Cochrane review on progestins for heavy menstrual bleeding confirmed that norethindrone reduces menstrual blood loss compared with placebo, but the included trials did not systematically report pharmacokinetic outcomes or drug interaction events, leaving clinicians to rely on case series and mechanistic extrapolation for interaction management in the HMB population specifically.